FAP-targeted PET/NIR in Lung Malignant Tumors

Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included. After receiving standard neoadjuvant therapy (chemotherapy/immunotherapy/combination therapy), FAPI-PET/CT and fluorescence imaging were performed one week before surgery. During the surgery, a near-infrared fluorescence navigation system was used to locate the tumor lesion. After surgery, the tumor bed range was determined by pathological gold standards (HE staining+immunohistochemistry), and the predictive efficacy and localization accuracy of FAPI-PET/fluorescence were compared and analyzed.

NCT Number	NCT07498933
Lead Sponsor	Peking University People's Hospital
Conditions	Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy
Enrollment	200 participants
Start Date	2025-06-03
Primary Completion	2027-10-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-01